BioNTech SE said yesterday that the COVID-19 vaccine it developed with Pfizer should be roughly as effective against the new coronavirus variant first detected in India as it has been shown to be against the South African variant.
The company said in a statement that Ugur Sahin, Chief Executive Officer, felt encouraged by recent findings in a scientific paper based on blood analysis of vaccinated individuals, which showed that the antibodies elicited by the vaccine were able to neutralise the Indian variant.
Since the blood tests on the variant that was first detected in South Africa had shown similar results, promising real-world data on the vaccine’s effectiveness against the South African variant of about 75 per cent led him to believe that its actual effectiveness against the Indian variant “might be in the same range.”
“So far, we’ve had the chance to test our vaccine against more than 30 variants of the virus. It has proven effective against mutations so far,” Sahin said earlier, speaking on Turkish television.
He added, “We expect (our vaccine) to protect against infections by 70 to 75 per cent,” he said on TV, in what the company later said was in reference to the South African variant and not directly to the Indian variant.
Since the concerning COVID-19 variant, known as B.1.617.2, was first identified in India, it has ravaged that country and spread to at least 26 nations out of the 53 in the World Health Organization’s (WHO) European region, the organisation said.
The WHO’s regional director said yesterday that COVID-19 vaccines being deployed in Europe, including the Pfizer/BioNTech shot, appear able to protect against circulating virus variants that have caused concern because they are more easily transmitted.
Sahin was speaking with Turkish Health Minister Fehrettin Koca, who separately said the country recorded less than 10,000 daily new coronavirus cases for the first time since 1st March.
Turkey, which briefly was second globally last month in new infections, is using the Pfizer/BioNTech vaccine as well as China’s Sinovac Biotech shot in its vaccination programme.
